A study has found that individuals on vegetarian diets have a lower risk of multiple myeloma and kidney, pancreatic, prostate ...
Morning Overview on MSN
Study: Colorectal cancer is now top cancer killer in Americans under 50
Colorectal cancer has claimed a grim new distinction among younger Americans. A research letter published in JAMA by American Cancer Society investigators found that the disease is now the leading ...
1don MSN
Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial
March 17 (Reuters) - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by 40% in patients with breast cancer. Here are some details: * Pfizer's ...
Live Science on MSN
Colorectal cancer is now the most common cause of cancer deaths in the US for people under 50
The American Cancer Society estimates that over 55,000 people will die from colorectal cancer in the U.S. this year. Of those, 7% will be under 50.
Women are more likely to survive cancer than men but face a higher risk of serious and adverse side effects from treatment, according to a landmark international study from Adelaide University.
An estimated 21,700 new cancers will be diagnosed among Iowans, and a projected 6,400 Iowans will die from cancer in 2026, 100 more than in 2025, according to the Iowa Cancer Registry’s 2026 report ...
A new report from the American Cancer Society found increases in rectal cancer are driving more colorectal cancer cases among ...
Community oncology practices reduce financial toxicity by offering 24% lower mean monthly care costs than hospital outpatient settings. Branded chemotherapy costs are 39% lower in community oncology ...
Iowa’s cancer rate is the second worst in the nation for three years running, and a comprehensive study being released today ...
Women using a certain type of hormone therapy to treat menopause symptoms could be at higher risk for breast cancer, according to a new study. The study, published Tuesday in The Lancet Oncology, ...
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results